Gerardo Aguilar-Monserrate

Gerardo Aguilar-Monserrate

Auto-generated profile, based on publicly available information

Gerardo Aguilar-Monserrate

11Hospital Clínico Universitario de Valladolid, Valladolid, Spain

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2024 in Blood
Verified
Journal Article
Closed access
PDF file
Tomás José González-LópezTomás José González-López
Tomás José González-López
NBNuria Bermejo-Vega
Nuria Bermejo-Vega
RCRocío Cardesa-Cabrera
Rocío Cardesa-Cabrera
VMVioleta Martínez-Robles
Violeta Martínez-Robles
GAGerardo Aguilar-Monserrate
Gerardo Aguilar-Monserrate
GGGloria García-Donas Gabaldón
Gloria García-Donas Gabaldón
Fostamatinib, a recently approved Syk inhibitor used in adult primary immune thrombocytopenia (ITP), has been shown to be safe and effective in this disorder. However, clinical trial results may not be similarly reproduced in clinical practice. Here, 138 patients with ITP (both primary and secondary) from 42 Spanish centers who had been treated with fostamatinib were evaluated prospectively and retrospectively. The median age of our cohort (55.8% women) was 66 years (interquartile range [IQR], 56-80). The median time since ITP diagnosis at fostamatinib initiation was 51 months (IQR, 10-166). The median number of therapies before fostamatinib initiation was 4 (IQR, 2-5), including eltrombopag (76.1%), romiplostim (57.2%), and IV immunoglobulins (44.2%). Fifty-eight patients (42.0%) had signs/symptoms of bleeding in the month before treatment initiation. Seventy-nine percent of patients responded to fostamatinib with 53.6% complete responses (platelet count > 100 × 109/L). Eighty-three patients (60.1%) received fostamatinib monotherapy, achieving a high response rate (85.4%). The proportion of time in response during the 27-month period examined was 83.3%. The median time to platelet response was 11 days (IQR, 7-21). Sixty-seven patients (48.5%) experienced adverse events, mainly grade 1 to 2; the commonest of which were diarrhea (n = 28) and hypertension (n = 21). One patient had deep venous thrombosis, and one patient developed acute myocardial infarction. Fostamatinib was shown to be effective with good safety profile in patients with primary and secondary ITP across a wide age spectrum in this real-world study.

29 October 2026 in Blood Advances
Verified
Journal Article
Closed access
LPLaura Palomo
Laura Palomo
MMMireia Morgades
Mireia Morgades
MMManja Meggendorfer
Manja Meggendorfer
MDMarina Díaz-Beyá
Marina Díaz-Beyá
HPHelena Pomares
Helena Pomares
BXBlanca Xicoy
Blanca Xicoy
Prognostication in chronic myelomonocytic leukemia (CMML) remains a challenge because of the biological complexity and variable clinical course of the disease. This study aimed to evaluate the prognostic utility of the Molecular International Prognostic Scoring System (IPSS-M) in CMML and its applicability across the myelodysplastic (MD) and myeloproliferative (MP) subsets of the disease. We conducted a multicenter, retrospective study including 511 patients diagnosed with CMML. Clinical, cytogenetic, and molecular data were collected at diagnosis, including targeted next-generation sequencing. Patients were stratified using IPSS-M, the molecular CMML-specific prognostic scoring system (CPSS-Mol), and the recently developed international CPSS (iCPSS). IPSS-M effectively stratified patients into risk groups with significantly different overall survival (OS) and cumulative incidence of acute myeloid leukemia (AML) progression. Discrimination was maintained after merging overlapping intermediate-risk categories, yielding a 4-tier model with a C-index of 0.678 for OS and 0.628 for AML progression, respectively. This model retained its prognostic performance in both MD-CMML and MP-CMML subsets, with a higher discrimination for OS in the MD-CMML group. When compared with CPSS-Mol and iCPSS, adapted IPSS-M showed comparable prognostic performance to iCPSS and improved discrimination compared with CPSS-Mol. These findings support the applicability of an adapted IPSS-M to CMML, extending its use beyond myelodysplastic syndromes and highlighting its potential utility in guiding clinical decision-making and therapeutic strategies. Moreover, this study provides an external validation of the iCPSS in an independent and genetically well-characterized CMML cohort, reinforcing its clinical utility.